Skip to main content
. Author manuscript; available in PMC: 2008 Feb 1.
Published in final edited form as: Cardiovasc Res. 2006 Nov 30;73(3):549–559. doi: 10.1016/j.cardiores.2006.11.031

Fig. 1.

Fig. 1

Effects of CeO2 nanoparticles on left ventricular function and remodeling. LV end-diastolic dimensions (LVEDD) (A) and percent fractional shortening (%FS) (B) were depicted from 2 to 6 months of age. The progressive LV dilatation and LV dysfunction in the vehicle-treated MCP mice were attenuated by treatment with CeO2 nanoparticles. *P<0.001 versus wild-type controls; #P < 0.05 versus vehicle-treated MCP mice; n=6 per group and per time point. Heart weight to body weight ratio (HW/BW) was depicted at 6 months of age (C). *P<0.001 versus wild-type controls; #P < 0.05 versus vehicle-treated MCP mice; n=5 per group.